Similar articles

• Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥ 70 mg/dl despite maximal tolerated cholesterol lowering therapy.

  Glueck CJ, Shah P, Goldenberg N, Prince M, Lee K, Jetty V, Kumar A, Goldenberg M, Wang P. Glueck CJ, et al. Lipids Health Dis. 2016 Mar 12;15:55. doi: 10.1186/s12944-016-0227-2. Lipids Health Dis. 2016. PMID: 26968977 Free PMC article.
• Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data.

  Strilchuk L, Fogacci F, Cicero AF. Strilchuk L, et al. Expert Opin Drug Saf. 2019 Jul;18(7):611-621. doi: 10.1080/14740338.2019.1620730. Epub 2019 May 29. Expert Opin Drug Saf. 2019. PMID: 31100030 Review.
• Quantitative silencing of EGFP reporter gene by self-assembled siRNA lipoplexes of LinOS and cholesterol.

  Metwally AA, Blagbrough IS, Mantell JM. Metwally AA, et al. Mol Pharm. 2012 Nov 5;9(11):3384-95. doi: 10.1021/mp300435x. Epub 2012 Oct 25. Mol Pharm. 2012. PMID: 23057412 Free PMC article.
• Cholesterol, cholesterol-lowering agents/statins, and urologic disease: Part III--A rapid review of FDA-approved cholesterol-lowering agents.

  Moyad MA, Merrick GS. Moyad MA, et al. Urol Nurs. 2006 Aug;26(4):330-2. Urol Nurs. 2006. PMID: 16939051
• Recent advances in the pharmacological management of hypercholesterolaemia.

  Ajufo E, Rader DJ. Ajufo E, et al. Lancet Diabetes Endocrinol. 2016 May;4(5):436-46. doi: 10.1016/S2213-8587(16)00074-7. Epub 2016 Mar 21. Lancet Diabetes Endocrinol. 2016. PMID: 27012540 Review.